FEASIBILITY AND SAFETY OF OUTPATIENT CONSOLIDATION CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA

EHA Library, Laura Curras Sanchez, 4160606

EFFICACY AND SAFETY OF VAC (VENETOCLAX, AZACITIDINE, CHIDAMIDE) REINDUCTION TREATMENT FOR UNFIT ACUTE MYELOID LEUKEMIA PATIENTS FAILED TO RESPOND TO ONE CYCLE OF VA INDUCTION

EHA Library, Shengli Xue, 4160607

MEASURABLE MINIMAL RESIDUAL DISEASE BY AN ULTRA-SENSITIVE NGS METHOD TO EVALUATE THE RESPONSE IN ACUTE MYELOID LEUKEMIA, THE VENAQUI CLINICAL TRIAL

EHA Library, Rosa María Ayala Díaz, 4160608

TOWARDS THE USE OF ARTIFICIAL INTELLIGENCE MODELS IN THE ASSESSMENT OF ACUTE PROMYELOCYTIC LEUKEMIA - SYSTEMATIC REVIEW

EHA Library, Mihnea-Alexandru Găman, 4160609

VEN-BASED SCHEMES, ARE THEY BETTER THAN '3 + 7'?

EHA Library, Pedro Amorim Machado, 4160610

ALLOGENEIC TRANSPLANTATION VS. CHEMOTHERAPY AS CONSOLIDATION STRATEGIES IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS AFTER FIRST COMPLETE REMISSION: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Cilomar Martins de Oliveira Filho, 4160611

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH AML FROM 65 TO 74 YEARS UNFIT FOR FIRST-LINE INTENSIVE CHEMOTHERAPY IN JAPAN.

EHA Library, Fumiaki Fujii, 4160612

THE FUS::ERG FUSION IN ACUTE MYELOID LEUKEMIA: INSIGHTS INTO MOLECULAR PROFILES AND PROGNOSTIC IMPLICATIONS

EHA Library, Bingbing Han, 4160613

HEALTHCARE RESOURCE UTILIZATION IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX COMPARED TO HIGH- AND LOW-INTENSITY NON-VENETOCLAX THERAPIES

EHA Library, Pinkal Desai, 4160614

PROGNOSTIC IMPACT OF THE AML60+ SCORE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS

EHA Library, Tobias Silzle, 4160615

OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND AZACITIDINE IN REAL-WORLD BELGIAN CLINICAL PRACTICE

EHA Library, Adrien De Voeght, 4160616

SURVIVAL ANALYSIS OF LONG-TERM TREATMENT WITH VENETOCLAX-AZACITIDINE IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: MULTICENTRE REAL-WORLD OUTCOMES IN CHINA

EHA Library, Jing Zou, 4160617

CLINICAL EXPERIENCE WITH HDAC INHIBITOR-BASED PROTOCOLS IN MECOM-REARRANGED ACUTE MYELOID LEUKEMIA

EHA Library, Eitan Kugler, 4160618

REAL-LIFE STUDY ON GILTERITINIB RELATED INFECTIONS (GILTERINF): AN ITALIAN SEIFEM STUDY

EHA Library, Elisa Buzzatti, 4160619

OUTCOMES OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN ACUTE MYELOID LEUKEMIA: THE THREE-SITE MAYO CLINIC CANCER CENTER EXPERIENCE.

EHA Library, Jabra Zarka, 4160620

VA COMBINED WITH LIPOSOMAL MITOXANTRONE: A NOVEL AND SAFE INDUCTION THERAPY FOR NEWLY DIAGNOSED AML

EHA Library, Yan Yu, 4160621

EFFECT OF OBESITY ON OVERALL SURVIVAL IN ELDERLY PATIENTS (>65 YEARS OLD) WITH ACUTE MYELOID LEUKEMIA - SINGLE-CENTER EXPERIENCE.

EHA Library, Karolina Bełdzińska-Gądek, 4160622

RELATIONSHIP BETWEEN SALVAGE STRATEGIES AND OUTCOMES IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA AFTER FIRST-LINE INTENSIVE CHEMOTHERAPY

EHA Library, Lucas Lefèvre, 4160623

THE PREDICTIVE ROLE OF HEMATOLOGIC RECOVERY IN THE PROGNOSIS OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH AZACITIDINE-VENETOCLAX

EHA Library, Yan Li, 4160624

CLINICAL EFFICACY AND SAFETY OF VENETOCLAX COMBINED WITH HOMOHARRINGTONINE, AZACITIDINE, AND CYTARABINE IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Xin Yan, 4160625

IN-DEPTH IMMUNE AND METABOLIC PROFILING OF GAIA/CLL13 PATIENTS TO UNCOVER TREATMENT-SPECIFIC CHANGES TO THE T-CELL COMPARTMENT [CJ1]

EHA Library, Chaja F Jacobs, 4160626

GUT MICROBIOME IMBALANCE DRIVES IMMUNE EXHAUSTION VIA SHORT-CHAIN FATTY ACIDS IN CLL

EHA Library, Monika Szelest, 4160628

THE LANDSCAPE OF CLONAL HEMATOPOIESIS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Othman Al-Sawaf, 4160629

EGR2 MUTATIONS COOPERATE IN ACTIVATING NOTCH-1 PATHWAY AND LEAD TO BTK INHIBITORS RESISTANCE IN CLL

EHA Library, Alessia Morabito, 4160630

DIAGNOSTIC CRITERIA FOR NK-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA: VALIDATION THROUGH A MULTICENTRIC INTERNATIONAL STUDY

EHA Library, Thierry Lamy, 4160631

A CLINICAL-MOLECULAR MODEL FOR A PERSONALISED PREDICTION OF TIME TO FIRST TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA

EHA Library, Aleix Real, 4160632

UNVEILING STAT3-DRIVEN CIRCULAR RNAS ALTERATIONS IN T-LARGE GRANULAR LYMPHOCYTE LEUKEMIA (T-LGLL)

EHA Library, Elisa Rampazzo, 4160633

CONTROLLED PERFUSION OF A VASCULARIZED SCAFFOLD WITHIN A 3D PRINTED BIOREACTOR TO STUDY CLL CELLS TRAFFICKING

EHA Library, Riccardo Pinos, 4160634

IMPACT OF TUMOR BURDEN AND PRIOR VENETOCLAX TREATMENT ON MOSUNETUZUMAB-MEDIATED TUMOR CONTROL IN RELAPSED/REFRACTORY CLL

EHA Library, Hyun Yong Jin, 4160635

GENOMIC CHARACTERIZATION OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ALTERATIONS FROM A SPANISH REAL-WORLD COHORT TREATED WITH TARGETED AGENTS

EHA Library, Joanna Kamaso, 4160636

UNCOVERING A CRITICAL ROLE FOR VAV1 IN α4ß1-BCR CROSSTALK IN CHRONIC LYMPHOCYTIC LEUKAEMIA: NOVEL INSIGHTS INTO DISEASE MECHANISMS

EHA Library, Tahera Alnassfan, 4160637

VENETOCLAX-ACALABRUTINIB FOR CLL PATIENTS RELAPSING AFTER VENETOCLAX-ANTICD20 TREATMENT: HIGHLY EFFECTIVE AND LOW TOXICITY. INTERIM ANALYSIS OF HOVON 159/REVEAL PHASE 2 TRIAL

EHA Library, Sabina Kersting, 4160638

ALLOGENEIC STEM CELL TRANSPLANTATION IS EFFECTIVE AFTER PATHWAY INHIBITOR TREATMENTS IN CLL; A RETROSPECTIVE STUDY ON BEHALF OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT

EHA Library, Michel van Gelder, 4160639

SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

EHA Library, Mazyar Shadman, 4160640

COMBINATION OF ZANUBRUTINIB + VENETOCLAX FOR TREATMENT-NAIVE CLL/SLL: RESULTS IN SEQUOIA ARM D

EHA Library, Mazyar Shadman, 4160641

MRD GUIDED MESUTOCLAX PLUS ORELABRUTINIB FOR CLL/SLL DEMONSTRATES HIGH RESPONSE AND EARLY MRD CLEARANCE WITH GOOD TOLERABILITY: PRELIMINARY ANALYSIS FROM AN ONGOING PHASE II DOSE OPTIMIZATION STUDY

EHA Library, Yang Liang, 4160642

USING MINIMAL RESIDUAL DISEASE STATUS TO GUIDE VENETOCLAX TREATMENT DURATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: INTERIM RESULTS FROM THE PHASE II VENETOSTOP STUDY

EHA Library, Leora Boussi, 4160643

A PHASE 1 STUDY OF SGR-1505, AN ORAL, POTENT MALT1 INHIBITOR FOR RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)

EHA Library, Stephen Spurgeon, 4160644

10-YEAR FOLLOW-UP OF A RANDOMIZED PHASE-2 STUDY OF IBRUTINIB OR IBRUTINIB PLUS RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Jan Burger, 4160645

SERIOUS INFECTIONS IN PATIENTS WITH CLL/SLL TREATED WITH COMBINATION VENETOCLAX AND OBINUTUZUMAB COMPARED WITH THOSE TREATED WITH ZANUBRUTINIB: A REAL-WORLD STUDY

EHA Library, Nicole Lamanna, 4160646

REAL-WORLD COMPARATIVE EFFECTIVENESS OF VENETOCLAX-OBINUTUZUMAB VERSUS SECOND-GENERATION BRUTON TYROSINE KINASE INHIBITORS IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Beenish Manzoor, 4160647

TREATMENT EFFECTIVENESS IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING VENETOCLAX-BASED THERAPY AFTER PROGRESSION ON A COVALENT BRUTON TYROSINE KINASE INHIBITOR (CBTKI)

EHA Library, Beenish Manzoor, 4160648

ANALYSIS OF COVID-19 INFECTIONS WITH FIXED-DURATION ACALABRUTINIB-VENETOCLAX COMBINATIONS IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA IN THE PHASE 3 AMPLIFY TRIAL

EHA Library, Jennifer R. Brown, 4160649

PHASE 1 STUDY OF FCN-338, A NOVEL BCL-2 INHIBITOR IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY

EHA Library, Huiqiang Huang, 4160650

IMPACT OF IBRUTINIB ON QUALITY OF LIFE IN PATIENTS WITH EARLY-STAGE, ASYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE PHASE III CLL12 TRIAL - MATCHING SAFETY TO PATIENT-REPORTED OUTCOMES

EHA Library, Ellinor Goergen, 4160651

DEVELOPMENT OF A CLINICAL MACHINE LEARNING TOOL FOR THE PREDICTION OF AUTOIMMUNE HEMOLYTIC ANEMIA IN CHRONIC LYMPHOCYTIC LEUKEMIA: A POPULATION BASED MULTILAYER PERCEPTRON MODEL

EHA Library, Rayan Ramadan, 4160652

REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIRST-LINE BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Ryan Jacobs, 4160653

FIRST WORLDWIDE REAL-LIFE DATA ON FIXED-DURATION IBRUTINIB+VENETOCLAX TREATMENT FOR PREVIOUSLY UNTREATED CLL/SLL PATIENTS: INITIAL INTERIM ANALYSIS OF SPAIN´S LI+VE OBSERVATIONAL STUDY

EHA Library, JOSE ANGEL HERNANDEZ RIVAS, 4160654

FIXED-DURATION BTKI-VENETOCLAX COMBINATIONS IN CLL: AN INDIRECT COMPARISON OF AMPLIFY AND CAPTIVATE TRIALS

EHA Library, Stefano Molica, 4160655

COMPARATIVE EFFICACY OF ZANUBRUTINIB VERSUS FIXED-DURATION ACALABRUTINIB PLUS VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

EHA Library, Talha Munir, 4160656

GENOTYPING OF SLC22A4 SNP RS460089 IN A REAL-LIFE CML COHORT: IMPLICATIONS FOR IMATINIB RESPONSE AND STABLE DMR ACHIEVEMENT

EHA Library, Katerina Machova, 4160657

OVERCOMING ASCIMINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA WITH IDENTIFICATION OF THERAPEUTIC STRATEGIES TARGETING BCR::ABL1 MUTATIONS

EHA Library, Seiichi Okabe, 4160658

LOW SERUM IL-8 MAY CONTRIBUTES TO TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA

EHA Library, Yuki Fujioka, 4160659

GERMLINE VARIANTS IN PEDIATRIC CHRONIC MYELOID LEUKEMIA

EHA Library, Tabita Ghete, 4160660

EARLY PREDICTION OF MR4.5 ATTAINMENT AND SUSTAINED RESPONSE IN CHRONIC MYELOID LEUKEMIA TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS: ANALYSIS FROM THE JALSG CML212 ROAD TO MR4.5 STUDY

EHA Library, TAKAAKI ONO, 4160661

PROSPECTIVE VALIDATION OF A DNA/RNA MRD-BASED RISK STRATIFICATION MODEL DURING TWO-PHASE TKI DOSE DE-ESCALATION FOR DISCONTINUATION IN CML

EHA Library, Katerina Machova, 4160662

IMPROVED PATIENT-REPORTED OUTCOMES (PROS) WITH ASCIMINIB (ASC) VS INVESTIGATOR-SELECTED TYROSINE KINASE INHIBITORS (IS-TKIS) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML): ASC4FIRST WK 48 ANALYSIS

EHA Library, Andreas Hochhaus, 4160663

RESULTS FROM THE FIRST-IN-CHILD PHASE II TRIAL (ITCC-054/COG-AAML1921) OF BOSUTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED (ND) CHRONIC MYELOID LEUKEMIA (CML).

EHA Library, Kim Schellekens, 4160664

ASSESSMENT OF TRANSITIONING FROM HIGH-POTENCY TO LOW-POTENCY INHIBITORS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: THE DOWNGRADING-IMPACT (D-IMPACT) PROJECT, A CML CAMPUS STUDY

EHA Library, Simona Bernardi, 4160665

THE FRONTLINE SECOND GENERATION TYROSINE KINASE INHIBITORS BRING TREATMENT-FREE REMISSION TO MORE PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Naoto Takahashi, 4160666

MYELOPROLIFERATIVE NEOPLASMS WITH CONCOMITANT CHRONIC MYELOID LEUKAEMIA ARE ASSOCIATED WITH TKI RESISTANCE AND POOR OUTCOMES: A REVIEW OF 46 CASES

EHA Library, Laura Li Gagnon, 4160667

ASC4OPT STUDY: HIGH EFFICACY AND FAVORABLE TOLERABILITY OF ASCIMINIB ONCE OR TWICE DAILY IN CML PATIENTS WITH SUBOPTIMAL RESPONSE, RESISTANCE OR INTOLERANCE OF 2 OR MORE TYROSINE KINASE INHIBITORS

EHA Library, Andreas Hochhaus, 4160668

UPDATED RESULTS OF MANAGED-ACCESS PROGRAM (MAP) OF ASCIMINIB USE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN 3 CLINICAL CENTERS.

EHA Library, Ekaterina Chelysheva, 4160669

IMPACT OF ADVERSE EVENTS ON QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA (CML) - RESULTS FROM THE PATIENT SURVEY ON HUMANISTIC BURDEN OF INTOLERANCE TO FIRST OR SECOND TKIS (SHIFT) STUDY IN THE US

EHA Library, David Wei, 4160670

CLINICAL FEATURES AND T CELL REPERTOIRE OF CHRONIC MYELOID LEUKEMIA PATIENTS WHO ATTEMPT DISCONTINUATION OF TYROSINE KINASE INHIBITORS: THE ISAC-TFR STUDY

EHA Library, Mai Fujita, 4160671

DEVELOPMENT OF A NOVEL SCORING TOOL TO PREDICT OPTIMAL RESPONSE IN CHRONIC MYELOID LEUKEMIA FOR IMPROVING TREATMENT EFFICACY BEYOND CURRENT RISK CLASSIFICATIONS

EHA Library, Kohjin Suzuki, 4160672

IMPACT OF PONATINIB TREATMENT ON PREGNANCY OUTCOMES

EHA Library, Elisabetta Abruzzese, 4160673

ANALYSIS OF FACTORS INFLUENCING TREATMENT-FREE REMISSION OUTCOMES AFTER IMATINIB DISCONTINUATION IN PAEDIATRIC CHRONIC MYELOID LEUKEMIA

EHA Library, Yanli Zhang, 4160674

SINGLE-CELL DERIVED TRANSCRIPTIONAL SIGNATURE OF DYSERYTHROPOIESIS STRATIFIES MDS WITH DIFFERENTIAL OUTCOMES AND RESPONSE TO LUSPATERCEPT

EHA Library, Kristian Gurashi, 4160675

TREATMENT ASSOCIATED CLONAL EVOLUTION IN HR-MDS AND AML- COMPREHENSIVE PROFILING IDENTIFIES BIOMARKERS AND TARGETABLE MECHANISMS OF ESCAPE

EHA Library, Paolo Mazzeo, 4160676

GALECTIN-1 AS A POTENTIAL NOVEL THERAPEUTIC TARGET IN CHRONIC MYELOMONOCYTIC LEUKAEMIA

EHA Library, Laura Guest, 4160677

SELECTIVE ASO-BASED JAK2 INHIBITOR FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH JAK2 V617F MUTATION BURDEN

EHA Library, Sandra Smieszek, 4160678

SOMATIC RUNX1 DELETIONS IN MYELODYSPLASTIC SYNDROME: A NOVEL RARE RECURRENT GENETIC ABERRATION ASSOCIATED WITH HIGH-RISK FOR TRANSFORMATION TO ACUTE MYELOID LEUKEMIA

EHA Library, Ahmed Al-Djaber, 4160679

ADAR1-MEDIATED RNA EDITING IN RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)

EHA Library, Ioannis Kotsianidis, 4160680

TRANSCRIPTIONAL ALTERATIONS IN THE BONE MARROW CELLS OF MYELODYSPLASTIC SYNDROME PATIENTS WITH MUTATIONS IN THE COHESIN SUBUNIT STAG2 ARE INDICATIVE OF REDUCED SENSITIVITY OF HEMATOPOIETIC STEM CELLS TO EXTRINSIC SIGNALS AND REDUCED IMMUNOGENIC POTENTIAL OF THEIR PROGENY

EHA Library, Marcus Buschbeck, 4160681

SINGLE-CELL TRANSCRIPTOMICS REVEALS BONE MARROW CHANGES IN MDS PATIENTS RESPONDING TO BEXMARILIMAB AND AZACYTIDINE

EHA Library, Jesper Mickos, 4160682

PROGENITOR IMBALANCE AND TRANSCRIPTIONAL DYSREGULATION AS POTENTIAL DRIVERS OF ABERRANT HEMATOPOIESIS IN MDS

EHA Library, Carmen Rodriguez-Res, 4160683

TRANSCRIPTIONAL REMODELING OF THE NON-IMMUNE BONE MARROW MICROENVIRONMENT IN MDS PATIENTS WITH SF3B1 MUTATIONS: INSIGHTS INTO BIOLOGY AND THERAPEUTIC IMPLICATIONS

EHA Library, Isabel A. Calvo, 4160684

IMPACT OF LUSPATERCEPT VS EPOETIN ALFA TREATMENT (TX) ON GENOMIC LANDSCAPE AND MUTATIONAL BURDEN IN PATIENTS (PTS) WITH LOWER-RISK (LR) MYELODYSPLASTIC SYNDROMES (MDS) IN THE COMMANDS TRIAL

EHA Library, Rami S. Komrokji, 4160685

CCR2-DIRECTED TARGETING OF MONOCYTIC-BIASED PROGENITOR AND MONOCYTIC POPULATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA AND ACUTE MONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 4160686

ARSENIC SULFIDE NANOCRYSTAL FORMULATION INCREASES EFFECTIVE ERYTHROPOIESIS OF MDS THROUGH SCAVENGING REACTIVE OXIDATIVE SPECIES AND STRESS GRANULES FORMATION

EHA Library, Tao Wang, 4160687

UTILITY OF SNP-ARRAY FOR DETECTING NUMERICAL ALTERATIONS AND LOSS OF HETEROZYGOSITY IN SMD AND CMML PATIENTS WITH NORMAL KARYOTYPE

EHA Library, Carmen Loredo Alvarez, 4160688

PATHOPHYSIOLOGICAL ABNORMALITIES OF RED BLOOD CELLS IN MYELODYSPLASTIC SYNDROMES AS POTENTIAL DIAGNOSTIC AND THERAPEUTIC MARKERS

EHA Library, Pinelopi Vryttia, 4160689

LUSPATERCEPT MODULATES THE TRANSCRIPTIONAL PROGRAM OF HSPCS OF MDS PATIENTS AT THE SINGLE CELL LEVEL.

EHA Library, Ioannis Kotsianidis, 4160690

ANALYSIS OF PREANALYTICAL VARIABILITY ON PLASMA MIRNA EXPRESSION PROFILE BY NEXT GENERATION SEQUENCING TO REVEAL SPECIFIC POTENTIAL DIAGNOSTIC BIOMARKERS OF MYELODYSPLASTIC SYNDROME.

EHA Library, Alessandra Giannella, 4160691

ROLE OF BYSTANDER CD8 T CELLS PRODUCING GRANZYME K IN MDS PROGRESSION

EHA Library, Yannick Simoni, 4160692

RISK STRATIFICATION IN HYPOMETHYLATING AGENT-TREATED PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A MULTIVARIATE MODEL (MDS-HOPE)

EHA Library, Kelly Chien, 4160693

SAFETY AND EFFICACY OF AZACITIDINE SEQUENTIAL SELINEXOR IN NEWLY DIAGNOSED PATIENTS WITH MYELODYSPLASTIC SYNDROMES EB1 OR EB2: A SINGLE-CENTER, SINGLE-ARM, PHASE IB/II TRIAL

EHA Library, Liya Ma, 4160694

GENOMIC AND CLINICOPATHOLOGIC DETERMINANTS OF OLIGOMONOCYTIC CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Guillermo Montalban-Bravo, 4160695

INVESTIGATION OF CHANGE IN IPSS-M AND MOLECULAR REMISSION STATUS AS PREDICTORS OF POST-TRANSPLANTATION OUTCOME - A NORDIC MULTICENTRE STUDY

EHA Library, Joel Wiggh, 4160696

OUTCOMES OF IMETELSTAT THERAPY IN PATIENTS WITH RING SIDEROBLAST-NEGATIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES FROM THE POOLED IMERGE STUDY POPULATIONS

EHA Library, Valeria Santini, 4160697

CLONAL HIERARCHY AND ALLELIC BURDEN ANALYSIS OF TET2 MUTATIONS IN MYELODYSPLASTIC NEOPLASMS

EHA Library, Yudi Zhang, 4160698

MEASURABLE RESIDUAL DISEASE IN CD34+ CELLS IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENIC STEM CELL TRANSPLANTATION

EHA Library, Carolin Lindholm, 4160699

THE ROLE OF THE ADENOSINERGIC PATHWAY IN THE RESPONSE TO AZACYTIDINE IN HR-MDS PATIENTS

EHA Library, Ioannis Kotsianidis, 4160700

RISK FACTORS OF PROGRESSION TO MYELOFIBROSIS IN PATIENTS WITH MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS WITH SF3B1 MUTATION AND THROMBOCYTOSIS

EHA Library, Fuhui Li, 4160701

ALLOGENEIC TRANSPLANTATION OUTCOMES OF MDS/AML: RISK VERIFICATION AND MATCHED ANALYSIS WITH AML—A MULTICENTER STUDY

EHA Library, Yuhua Ru, 4160702

A PHASE 2 PROSPECTIVE STUDY EVALUATING LOW-DOSE DEFERASIROX IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME RESISTANT OR RELAPSING AFTER ERYTHROPOIETIN STIMULATING AGENTS (LODEFI)

EHA Library, Mathieu Meunier, 4160703

OUTCOMES OF ALLOGENEIC TRANSPLANTATION FOR SECONDARY MYELODYSPLASTIC SYNDROME EVOLVED FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Machiko Fujioka, 4160704

A PHASE I DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF F182112, BCMA X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, mingyuan Sun, 4160705

A PHASE 2, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF OB756, A NOVEL JAK2 INHIBITOR, IN JAK INHIBITOR-NAÏVE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Library, Jian Huang, 4160706